
Grace Therapeutics, Inc. (GRCE)
Last updated: 2026-10-24 16:34:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Grace Therapeutics, Inc. (GRCE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.92, with a market capitalization of $40.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.79 to $5.18. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$40.28M | |
$1.91 | |
$5.18 | |
$1.75 | |
$1.92 | |
46.81K | |
163.53K | |
-- | |
$5.18 | |
$1.79 | |
-- | |
-- |
Grace Therapeutics, Inc. (GRCE) Latest Closing Stock Price
Grace Therapeutics, Inc. (GRCE) last closed at $1.92 as of 2026-10-23 23:31:00, unchanged from the previous close of $1.92.
During the latest regular trading session, GRCE traded between $1.75 and $5.18, with a volume of 46.81K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Grace Therapeutics, Inc. (GRCE) 7-Day Stock Price Change
Over the past seven days, Grace Therapeutics, Inc. (GRCE) moved from $1.95 to $1.92, representing a decline of 1.79% ($0.03).
The stock traded between $1.82 and $2.07 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 97.77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
GRCE 52-Week Price Position
Position in Range: 3.7%
GRCE is currently trading at $1.92, placing it 3.7% of the way from its 52-week low of $1.79 to its 52-week high of $5.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Grace Therapeutics, Inc. (GRCE)?
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Grace Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Grace Therapeutics, Inc. (GRCE) Stock on MEXC
Eligible investors can buy real shares of Grace Therapeutics, Inc. (GRCE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Grace Therapeutics, Inc. (GRCE) stock price today?
2.Is GRCE stock going up or down today?
3.What is GRCE pre-market price?
4.What is GRCE after-hours price?
5.Is GRCE stock trading now?
6.Where does GRCE sit relative to its 52-week high and low?
7.What sector is Grace Therapeutics, Inc. in?
8.What is Grace Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is GRCE valued in terms of P/E ratio and EPS?
10.Does Grace Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
GRCE Stock Calculator
Estimate the value between GRCE shares and USD.
GRCE Shares to USD
1.00 GRCE shares = 1.915 USD
Calculations are estimates based on the latest available price and are for reference only.


